U.S. Retail Distributors Stock News

Novavax: recent performance snapshot for retail investors Novavax (NVAX) has drawn attention after recent share price swings, with the stock closing at US$7.97 and showing mixed returns over the past month and past 3 months. For context, the company reports annual revenue of US$1.12b from recombinant vaccines, including its commercialized COVID-19 product Nuvaxovid and the R21 Matrix-M adjuvant malaria vaccine. See our latest analysis for Novavax. The recent 1 day share price return of 3.51%...

Teledyne Technologies (TDY) is back in focus after a series of new defense, marine, and space contracts, including an upgrade to its Prism SKR autonomy software that reframes how guided systems handle mission execution. See our latest analysis for Teledyne Technologies. Those defense, marine, and space wins come as Teledyne Technologies’ share price sits at US$632.01, with a 7 day share price return of 8.21% and a 90 day share price return of 18.64%, while the 1 year total shareholder return...

Green Brick Partners (GRBK) is drawing fresh investor attention after announcing Rainwater Crossing, a master planned community in Celina, Texas that combines new model homes, multiple builders, extensive amenities and public art. See our latest analysis for Green Brick Partners. Alongside the Rainwater Crossing announcement, Green Brick Partners’ share price has moved to US$66.26, with a 7 day share price return of 5.59% but a 30 day share price return of a 3.00% decline. The 1 year total...

Wondering whether Vera Therapeutics at around US$40.45 is still offering value, or if the easy gains are behind it? This article is designed to help you frame that question clearly. The stock has returned 6.2% over the last week and 3.5% over the last month, while year to date it is down 16.8% but up 102.8% over the past year and a very large amount over three years. This naturally raises questions about what is already priced in. Recent coverage has focused on Vera Therapeutics as investors...

Align Technology (ALGN) is back in focus after a run of analyst upgrades tied to its recent earnings performance, with revenue and net income both showing year over year growth and valuation metrics attracting fresh investor attention. See our latest analysis for Align Technology. At a share price of US$171.87, Align’s recent 7 day share price return of 3.37% and year to date share price return of 10.15% sit against a 1 year total shareholder return of 12.08%, while the 3 year and 5 year...

Why Red Rock Resorts is on investors’ radar today Red Rock Resorts (RRR) has drawn investor attention after recent share price moves, with the stock up 1.3% over the past week but showing a 3.4% decline over the past month. See our latest analysis for Red Rock Resorts. While the recent 6.8% 7 day share price return stands out against an 11.5% year to date share price decline, the 1 year total shareholder return of 53.0% shows that longer term investors have still seen strong gains. If recent...

In March 2026, Accenture announced that Hormel Foods had completed the integration of o9 Solutions’ AI-powered demand and supply planning platform across more than 70 dry and refrigerated network sites, unifying previously disconnected planning tools for its complex global supply chain. This move gives Hormel Foods an enterprise-wide “digital brain” to better synchronize demand signals with inventory, production, and logistics decisions across brands from SPAM and SKIPPY to PLANTERS and...

Why Exelon (EXC) is on investors’ radar right now Exelon (EXC) has drawn attention after recent share performance, with a modest negative move over the past week and month, alongside a positive total return over the past 3 months and year. For investors tracking utilities, Exelon’s current share price of $48.94, market value of about $50.5b, and value score of 3 provide a starting point for thinking about how the stock fits into a broader portfolio. See our latest analysis for Exelon. Recent...

Crinetics Pharmaceuticals (CRNX) recently submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, supported by data from 18 clinical trials, including two Phase 3 studies that met all primary and secondary endpoints. See our latest analysis for Crinetics Pharmaceuticals. The Brazil filing arrives after a strong run in recent days, with a 7 day share price return of 10.01% partly offsetting a weaker year to date share price return of 19.32% and contrasting with a 1...

In late March 2026, Guardant Health announced that its InfinityAI real-world evidence platform was used alongside clinical trial data to support Japan’s approval of Daiichi Sankyo’s ENHERTU for treating HER2-positive advanced or recurrent solid cancers refractory or intolerant to standard therapies. This use of InfinityAI highlights how Guardant’s clinicogenomic data and artificial intelligence can help regulators assess outcomes in genomic subpopulations that are difficult to enroll in...

Builders FirstSource (BLDR) is back in focus after a recent quarter in which it missed analysts' revenue and EBITDA estimates but still raised full-year guidance, a rare move among peers. See our latest analysis for Builders FirstSource. The share price tells a mixed story: the 1-day share price return of 3.7% and 7-day gain of 4.1% come after a 30-day share price decline of 11.9% and a 1-year total shareholder return of 31% in the red. This suggests momentum has cooled even as guidance...

Investor focus on FTAI Aviation (FTAI) sharpened after the U.S. President signaled willingness to ease military tensions, a shift that coincided with a 4% stock move and calmer energy and industrial sector sentiment. See our latest analysis for FTAI Aviation. For context, FTAI Aviation’s 1-day share price return of 1.70%, 7-day share price return of 7.89% and year to date share price return of 17.34% sit against a very large 1-year total shareholder return. This suggests momentum has been...

Generac Holdings Inc. and CPower Energy recently announced a collaboration to deploy distributed generation solutions, including battery storage, generators and microgrids, for commercial and industrial customers across PJM, enabling participation in capacity, ancillary services, energy and on-bill programs. This partnership marries Generac’s equipment and dealer network with CPower’s demand response expertise at a time of rising electricity demand and historically high power prices,...

Recently, Jefferies highlighted MasTec’s record fourth-quarter revenue of US$3.90 billion and a growing 18‑month backlog of US$19.00 billion, supported by strength across all four business segments. The firm’s comments emphasize how MasTec’s expanding backlog and execution in energy, communications, power, and infrastructure are reinforcing confidence in its multi-year project pipeline. Next, we’ll examine how MasTec’s record revenue and expanding backlog could influence the existing...

Madison Square Garden Entertainment recently received fresh analyst attention with BTIG initiating coverage and the company advancing talks to bring its large-scale immersive Sphere venue concept to Tokyo, alongside appointing Allen Lo as Executive Vice President and Chief Legal Officer in late March. Together, the analyst endorsement and potential Tokyo Sphere highlight how MSG Entertainment is pushing its immersive live-event format beyond its core U.S. venues, which could gradually reduce...

A California federal judge has allowed a class action deceptive pricing lawsuit against Abercrombie & Fitch's Hollister brand to move forward. The ruling denies Abercrombie & Fitch's motions to dismiss the case or compel arbitration, keeping the claims in open court. Plaintiffs allege Hollister used fake reference prices online to create the appearance of discounts for shoppers. The ruling puts NYSE:ANF and its Hollister brand under closer legal and public scrutiny at a time when the...

RH (RH) stock was hit hard after fourth quarter results missed analyst expectations. The company also issued softer fiscal 2026 guidance, citing tariff shifts, macro pressures, and elevated international expansion spending. See our latest analysis for RH. The latest sell off leaves RH at a share price of $118.65, with a 30 day share price return of 16.54% and a 90 day share price return of 43.55%. At the same time, the 1 year total shareholder return of 27.86% and 5 year total shareholder...

Tractor Supply Company recently reported a softer fourth quarter, with revenue growing year on year but missing analysts’ expectations and leading management to issue full‑year earnings guidance and EBITDA that also came in below forecasts. In contrast, the company has continued to invest in community engagement, launching an FFA-exclusive contest for its 2026 Harvest Fest tote bag to support youth education and highlight its rural lifestyle brand. We’ll now examine how the recent earnings...

Celcuity Inc. recently reported fourth-quarter 2025 results showing a net loss of US$50.97 million, with basic loss per share from continuing operations of US$0.97, and a full-year 2025 net loss of US$177.04 million, or US$3.79 per share, both higher than the prior year. The sharp year-on-year increase in reported net loss highlights the cost of Celcuity’s ongoing development and commercialization efforts as it remains a pre-revenue, clinical-stage biotechnology company. With losses widening...

Casella Waste Systems stock moves after recent share performance Casella Waste Systems (CWST) has caught investor attention after a mixed recent run, with the stock up around 10% over the past week but showing declines over the month and past 3 months. See our latest analysis for Casella Waste Systems. At a share price of $86.23, Casella’s recent 10% 7 day share price return contrasts with weaker 1 month and year to date share price returns. The 1 year total shareholder return of 17.11% and 5...

Investors may be wondering whether Sanmina's share price still reflects good value after its run in recent years, or if most of the opportunity is already priced in. The stock last closed at US$129.29, with returns of 4.2% over 7 days and 5.1% over 30 days. Year to date performance sits at an 18.8% decline, compared with an 83.1% return over 1 year and 127.6% over 3 years. Recent attention on Sanmina has focused on how the business is positioned within the broader technology sector, as...

Citigroup’s downgrade of Bio-Rad Laboratories (BIO) from Buy to Neutral, along with a sharp cut to its price target, has put fresh attention on how investors assess the stock after recent share price moves. See our latest analysis for Bio-Rad Laboratories. At a share price of US$278.85, Bio-Rad’s 1-day share price return of a 0.41% decline sits against a 7-day gain of 3.14% and a 90-day share price return of a 14.33% decline. The 1-year total shareholder return of 21.56% contrasts sharply...

Fidelity National Financial (FNF) is back in focus after several AI driven models downgraded the stock, citing weakening cash flows, recent GAAP net losses, and bearish technical indicators that have raised questions around dividend durability. See our latest analysis for Fidelity National Financial. Recent AI driven downgrades and concerns around cash flows help explain why the 30 day share price return sits at a 6.99% decline and the year to date share price return is down 14.19%, even...

Rhythm Pharmaceuticals recently received a positive opinion from the European Medicines Agency’s CHMP to expand IMCIVREE’s authorization to acquired hypothalamic obesity, and appointed veteran life sciences leader Kim Popovits to its Board, succeeding Ed Mathers. This combination of potential European label expansion for IMCIVREE and added commercialization expertise on the Board may meaningfully influence how Rhythm executes its rare neuroendocrine disease focus. Next, we’ll examine how the...